Canntab Therapeutics Limited Share Price Deutsche Boerse AG
Equities
TBF1
CA1377991023
Pharmaceuticals
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0005 EUR | -.--% | -.--% | -.--% |
04-15 | Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding | CI |
2023 | Canntab Therapeutics Limited Provide an Update on Product Delivery | CI |
Sales 2021 | - | Sales 2022 | 0.29 0.27 23.38 | Capitalization | 11.48M 10.71M 915M |
---|---|---|---|---|---|
Net income 2021 | -4M -3.73M -319M | Net income 2022 | -3M -2.8M -239M | EV / Sales 2021 | - |
Net Debt 2021 | 75.05K 70.03K 5.98M | Net Debt 2022 | 1.15M 1.07M 91.57M | EV / Sales 2022 | 43,043,762 x |
P/E ratio 2021 |
-7.9
x | P/E ratio 2022 |
-3.02
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 86.26% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 19/04/16 | |
President | 56 | 19/04/16 | |
Chief Tech/Sci/R&D Officer | - | 14/05/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
President | 56 | 19/04/16 | |
Barry Polisuk
BRD | Director/Board Member | 61 | 10/04/18 |
Vitor Fonseca
BRD | Director/Board Member | 71 | 10/04/18 |
1st Jan change | Capi. | |
---|---|---|
+35.04% | 5.92B | |
-15.13% | 4.51B | |
-9.75% | 3.15B | |
+2.14% | 3.1B | |
-6.82% | 2.42B | |
+47.87% | 1.97B | |
-7.89% | 1.68B | |
+0.09% | 1.65B | |
-12.97% | 1.53B |
- Stock Market
- Equities
- PILL Stock
- TBF1 Stock